Nov. 21 at 1:41 PM
$ABCL
Simply put, if Abdera hits, AbCellera gets paid. If Abdera hits multiple times, AbCellera gets paid multiple times. This is a real, tangible example of the “shots on goal” model that many people assume is theoretical or far in the future. It’s happening right now, with a partner that has serious scientific traction.
And I know Abdera has their own plaform, but I think its important to distinguish what each does.
AbCellera’s platform: Used to discover and optimize antibodies. Think of it as finding the best antibodies with high specificity and good drug properties.
Abdera’s ROVEr™ platform: Used to turn those antibodies into radiopharmaceuticals. It attaches radioactive isotopes, tunes how the drug behaves in the body, and makes it effective and safe for cancer therapy.
